RHB-104
Phase 3Small molecule
RHB-104 is one of 54 small molecule programs targeting Multiple Sclerosis. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
RHB-104
RRedHill Biopharma Limited
Phase 3
Zinbryta
RochePreclinical
Pred Forte
NovartisPreclinical
Myfortic
NovartisPreclinical
Novantrone
PfizerPreclinical
Circadin
NNeurim Pharmaceuticals Ltd.
Preclinical
Lunesta
Akero TherapeuticsPreclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Multiple Sclerosis1 trial
Tuberculosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RHB-104. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRedHill Biopharma Limited